A cytomegalovirus-based therapeutic vaccine against oncogenic human papillomaviruses
Ended Cooperative Agreement Awarded Last action
- Award ID
- R44CA180177
- Recipient
-
Tomegavax, Inc. UEI NUE6Q16X2GL1
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,876,513
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- Portland, OR 97239, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $928,329 | |
| Original award | $948,184 |
Quick answers
Who received award R44CA180177?
R44CA180177 was awarded to Tomegavax, Inc. by National Cancer Institute (National Institutes of Health) on June 13, 2014.
How much is award R44CA180177 worth?
$1,876,513 has been obligated on R44CA180177.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award